Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-07 · 1881 (3) · 189570
DOI: 10.1016/j.bbcan.2026.189570 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-07. Verfasst von Anjali Prasad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States of America. Hauptthemen laut MEDLINE: Mitochondria, Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, Mayo Clinic.
Abstract (Originalsprache)
High-grade serous ovarian cancer (HGSOC) is often programmed to rely heavily on mitochondrial metabolism, an adaptation that is linked to disease progression as well as resistance to standard treatments and immunotherapies. As such, mitochondrial metabolism has emerged as a promising therapeutic vulnerability to overcome resistance and selectively eliminate HGSOC cells. Several agents targeting mitochondrial metabolism are currently in or advancing toward clinical trials for various cancers. Additionally, multiple FDA-approved drugs have been repurposed to target this metabolism, and recent studies demonstrate their potential use in HGSOC therapy. This review describes the molecular mechanisms underlying mitochondrial metabolic rewiring in HGSOC and outlines the role of this rewiring in disease progression, immune evasion, and treatment resistance. In addition, we discuss current challenges and potential strategies to exploit this metabolic remodeling for more effective treatment of HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States of America.
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States of America; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, United States of America.
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States of America; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, United States of America. Electro…
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- Mayo Clinic
- Ovarian Cancer Research Alliance
- National Institutes of Health
- Ovarian Cancer Research Fund Alliance
- Minnesota Ovarian Cancer Alliance
Zitieren
APA
Prasad, A., Kaufmann, S. H., & Kanakkanthara, A. (2026). Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(3), 189570. https://doi.org/10.1016/j.bbcan.2026.189570
Vancouver
Prasad A, Kaufmann SH, Kanakkanthara A. Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(3):189570. doi:10.1016/j.bbcan.2026.189570
BibTeX
@article{Prasad2026,
author = {Prasad, Anjali and Kaufmann, Scott H and Kanakkanthara, Arun},
title = {Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {3},
pages = {189570},
doi = {10.1016/j.bbcan.2026.189570}
}
EUVIMED